克拉斯
间变性淋巴瘤激酶
表皮生长因子受体
靶向治疗
癌症
肺癌
医学
克里唑蒂尼
病毒癌基因
肉瘤
生物
癌症研究
肿瘤科
内科学
病理
结直肠癌
恶性胸腔积液
作者
Suman Rohilla,Mahaveer Singh,Sami I. Alzarea,Waleed H. Almalki,Fahad A. Al‐Abbasi,Imran Kazmi,Obaid Afzal,Abdulmalik Saleh Alfawaz Altamimi,Sachin Kumar Singh,Dinesh Kumar Chellappan,Kamal Dua,Gaurav Gupta
出处
期刊:Journal of Environmental Pathology Toxicology and Oncology
[Begell House Inc.]
日期:2023-01-01
卷期号:42 (1): 27-50
被引量:22
标识
DOI:10.1615/jenvironpatholtoxicoloncol.2022042983
摘要
Treatment of lung cancer with conventional therapies, which include radiation, surgery, and chemotherapy results in multiple undesirable adverse or side effects. The major clinical challenge in developing new drug therapies for lung cancer is resistance, which involves mutations and disturbance in various signaling pathways. Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC). But, inevitable development of resistance presents limits the clinical benefits of various new drugs. Here, we review current progress in the development of molecularly targeted therapies, concerning six clinical biomarkers: EGFR, ALK, MET, ROS-1, KRAS, and B-RAF for NSCLC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI